Physician profile
Devin A Mcmanus
NPI 1548263486
$6,738.96
in general payments reported to CMS, 2019-2025
41 companies · $892 in 2025
The $892 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,670 · 2020: $1,169 · 2021: $309 · 2022: $549 · 2023: $880 · 2024: $1,271 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,990 · Education: $52.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,990.15 |
| Education | $52.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,105.80 | 2019-2024 | Xarelto |
| Amgen INC. | $1,075.44 | 2019-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $646.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $554.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $477.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.32 | 2019-2022 | |
| Mylan Specialty L.P. | $331.16 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $248.16 | 2019-2025 | |
| Abbvie INC. | $157.40 | 2019-2024 | |
| Amarin Pharma, INC. | $130.83 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $128.86 | 2019-2020 | |
| Lilly USA, LLC | $127.87 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Sanofi-Aventis U.S. LLC | $111.79 | 2019 | |
| Kci USA, INC. | $101.04 | 2023 | Activ.A.C., V.A.C. Dermatac, 3m Cavilon |
| Abbott Laboratories | $97.49 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.